Contineum Therapeutics (CTNM) RBC Capital Markets Global Healthcare Conference 2026 summary

Clinical trial updates and data insights

• Exploratory phase I-B study of PIPE-791 in chronic pain showed promising trends in pain reduction and responder rates, with stronger efficacy signals in osteoarthritis compared to lower back pain due to disease homogeneity.

• Primary endpoint of safety and tolerability was met, with a benign adverse event profile and no significant hemodynamic or cardiac issues observed at high doses.

• Four weeks of dosing at high receptor occupancy increased confidence in safety, especially compared to competitors with hypotension signals.

• Central activity of PIPE-791 is believed to mediate pain improvement, supported by animal model data and unique mechanism targeting LPA1 receptor.

• Focus remains on IPF and pulmonary fibrosis, with plans to consider further pain studies after additional data review and stakeholder engagement.

Competitive landscape and differentiation

• PIPE-791 offers potential differentiation from competitors through once-daily dosing, extended receptor occupancy, and lack of blood pressure issues.

• Quality of life improvements, including pain reduction, are being explored as additional differentiators.

• Ongoing phase II trial in IPF is designed for robust, well-controlled comparison, with potential for parallel phase III studies in PPF.

• LPA1 antagonism is positioned as a potential backbone therapy in IPF/PPF, with flexibility to combine with other emerging treatments.

Pipeline, partnerships, and financials

• PIPE-307 is being developed for MDD by a partner, with data expected in the second half of the year; prior MS trial missed its primary endpoint but was safe.

• No immediate plans to partner PIPE-791; partnering discussions are focused on earlier-stage assets.

• Patent coverage for PIPE-791 extends to 2042, potentially to 2044 with extensions.

• Company is well-funded with $250 million in cash, providing runway through mid-2029 and covering the completion of the phase II PROPEL-IPF study.